{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:52:23Z","timestamp":1793731943088,"version":"4.6.1"},"reference-count":49,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Appl Thromb Hemost"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cerebral venous thrombosis (CVT) is a rare but severe type of stroke, typically treated with vitamin K antagonists (VKAs). This study compares different direct oral anticoagulants (DOACs) with VKAs for the management of CVT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Cochrane Central, and ScienceDirect were searched up to May 2025. A network meta-analysis using a frequentist approach was performed in RStudio version 4.3.3. P-scores were used to rank treatments. The evaluated outcomes included full recanalization, recurrent venous thromboembolism (VTE), major hemorrhage, intracranial hemorrhage (ICH), and mortality. The Cochrane Risk of Bias (RoB 2.0) tool and the Newcastle-Ottawa Scale (NOS) were employed to assess the quality of randomized controlled trials (RCTs) and observational studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our analysis included 16 studies involving 1403 patients. We found that various DOACs, including apixaban, dabigatran, and rivaroxaban, had rates of full recanalization, VTE recurrence, major hemorrhage, ICH, and mortality comparable to those of VKAs. VKAs showed the highest likelihood of full recanalization, with a P-score of 0.70, whereas apixaban had the lowest, with a P-score of 0.04. For reducing recurrent VTE rates, apixaban was the most effective (P-score = 0.83), and dabigatran the least (P-score = 0.04). Apixaban also led to the greatest reduction in ICH risk (P-score = 0.70), while rivaroxaban had the lowest likelihood (P-score = 0.29). Regarding major hemorrhage, apixaban had the highest probability of reduction (P-score = 0.81), with VKAs performing worst (P-score = 0.26). Lastly, apixaban ranked highest for reducing mortality (P-score = 0.78), whereas VKAs ranked lowest (P-score = 0.39).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>DOACs showed no significant differences in rates of full recanalization, VTE recurrence, major hemorrhage, ICH, or mortality compared with VKAs. Apixaban had the highest probability of reducing VTE recurrence, mortality, and hemorrhagic events, whereas VKAs had the highest probability of achieving full recanalization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10760296261427166","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T19:18:51Z","timestamp":1773256731000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparing Efficacy and Safety of Different Anticoagulants in Cerebral Venous Thrombosis: A Systematic Review and Network Meta-Analysis"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4521-3256","authenticated-orcid":false,"given":"Muhammad Hassan","family":"Waseem","sequence":"first","affiliation":[{"name":"Allama Iqbal Medical College"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zain ul","family":"Abideen","sequence":"additional","affiliation":[{"name":"King Edward Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamir Pitton","family":"Rissardo","sequence":"additional","affiliation":[{"name":"Cooper University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Haris","family":"Khan","sequence":"additional","affiliation":[{"name":"Saidu Medical College"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanza","family":"Farhan","sequence":"additional","affiliation":[{"name":"Jinnah Sindh Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Leticia","family":"Fornari Caprara","sequence":"additional","affiliation":[{"name":"Cooper University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2085-8739","authenticated-orcid":false,"given":"Pawan Kumar","family":"Thada","sequence":"additional","affiliation":[{"name":"Sotang Primary Hospital, Solukhumbu, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam A.","family":"Dmytriw","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital"},{"name":"Neurointerventional &amp; Neuroanalytics Collaboration (NAN-C), School of Medicine, Toronto Metropolitan University, Toronto, ON"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.122.039579"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.597623"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2018.07.023"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2022.05.142"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/10760296241256360"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/10760296251316869"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/10760296251405417"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.49017"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2025.108290"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12316"},{"key":"e_1_3_2_12_2","first-page":"372","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Br Med J. 2021:372.","journal-title":"Br Med J."},{"key":"e_1_3_2_13_2","first-page":"1","article-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins JPT","year":"2019","unstructured":"Higgins JPT, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions. Cochrane Handbook for Systematic Reviews of Interventions. 2019:1-694.","journal-title":"Cochrane Handbook for Systematic Reviews of Interventions"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01204.x"},{"key":"e_1_3_2_15_2","first-page":"366","article-title":"Rob 2: A revised tool for assessing risk of bias in randomised trials","author":"Sterne JAC","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. Rob 2: A revised tool for assessing risk of bias in randomised trials. Br Med J. 2019:366.","journal-title":"Br Med J."},{"key":"e_1_3_2_16_2","unstructured":"Wells GA. 2014. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"issue":"1","key":"e_1_3_2_19_2","article-title":"Rivaroxaban versus warfarin for the treatment of cerebral venous thrombosis (RWCVT): A randomized controlled trial in resource-limited setting","volume":"2025","author":"Alkhawam A","year":"2025","unstructured":"Alkhawam A, Okar L, Hanafi I, et al. Rivaroxaban versus warfarin for the treatment of cerebral venous thrombosis (RWCVT): A randomized controlled trial in resource-limited setting. Stroke Res Treat. 2025;2025(1).","journal-title":"Stroke Res Treat"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-021-01651-z"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/4979210"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-021-02091-1"},{"issue":"3","key":"e_1_3_2_23_2","first-page":"5","article-title":"Clinical observation of rivaroxaban and warfarin in the treatment of cerebral venous Sinus thrombosis","volume":"12","author":"Fei-hu L","year":"2022","unstructured":"Fei-hu L, Xue Y. Clinical observation of rivaroxaban and warfarin in the treatment of cerebral venous Sinus thrombosis. ACTA NEUROPHARMACOLOGICA. 2022;12(3):5.","journal-title":"ACTA NEUROPHARMACOLOGICA"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.2764"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.123.044113"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.114.006167"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/10760296221144038"},{"issue":"3","key":"e_1_3_2_28_2","first-page":"125","article-title":"Evaluation of rivaroxaban versus warfarin for the treatment of cerebral vein thrombosis: A case-control blinded study","volume":"20","author":"Khorvash F","year":"2021","unstructured":"Khorvash F, Farajpour-Khanaposhtani MJ, Hemasian H, Saadatnia SM. Evaluation of rivaroxaban versus warfarin for the treatment of cerebral vein thrombosis: A case-control blinded study. Curr J Neurol. 2021;20(3):125-130.","journal-title":"Curr J Neurol"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/17474930241234749"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1080\/21556660.2020.1838769"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-021-02595-0"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1404099"},{"key":"e_1_3_2_33_2","first-page":"8487","article-title":"Comparison of warfarin and rivaroxaban in treatment of cerebral venous sinus thrombosis","volume":"6","author":"Saeed FA","year":"2019","unstructured":"Saeed FA, Ahmad ZN. Comparison of warfarin and rivaroxaban in treatment of cerebral venous sinus thrombosis. Indo Am J Pharm Sci. 2019;6:8487-8492.","journal-title":"Indo Am J Pharm Sci"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00519-2"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12424"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1186\/s42466-024-00320-9"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.017559"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14092914"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.1869"},{"key":"e_1_3_2_40_2","unstructured":"Perry T. 2023. Apixaban is safer and more effective than rivaroxaban for non-valvular atrial fibrillation."},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.4103\/picr.picr_171_21"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.2147\/DHPS.S74410"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.100143"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30191-1"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.101714"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00775-z"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp110418"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-011-0551-3"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000456"}],"container-title":["Clinical and Applied Thrombosis\/Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10760296261427166","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10760296261427166","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10760296261427166","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T10:15:07Z","timestamp":1779185707000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10760296261427166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":49,"alternative-id":["10.1177\/10760296261427166"],"URL":"https:\/\/doi.org\/10.1177\/10760296261427166","relation":{},"ISSN":["1076-0296","1938-2723"],"issn-type":[{"value":"1076-0296","type":"print"},{"value":"1938-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"10760296261427166"}}